来宝网Logo

热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

现在位置首页>技术资料首页>行业动态>公司动态>微创医疗与意大利索林成立合资公司

微创医疗与意大利索林成立合资公司

互联网2014年1月10日 9:56 点击:10020

微创医疗  MicroPort     意大利索林集团Sorin Group

微创集团与索林集团签署合资协议 在华共建心律管理业务平台

  中国上海,2014年1月9日—微创集团(HK:853) 和索林集团(路透社代码:SORN.MI)今日在上海正式签订协议,将在华组建新合资公司微创索林心律管理(上海)有限公司(下称“微创索林心律管理”),共同研发、生产和营销心律管理器械(包括起搏器、ICD及CRT等),微创集团持51%股权,索林集团持49%股权。

 
      微创索林心律管理总部将设在上海,计划于2014年上半年正式运行。索林集团是一家非常注重创新的企业,有逾40年的心律管理器械开发制造经验;微创集团在中国拥有领先的市场覆盖率和销售渠道,也已在该领域持续投入了近5年的高强度研发。通过双方的业务优化整合能实现优势互补,产生协同的规模效应,有望能迅速渗入快速增长的中国心律管理市场。业内研究显示,中国心律管理市场市值总额达5亿美元,未来5年其年均增长率超过10%。
 
      微创集团董事长兼首席执行官常兆华博士表示:“微创集团与索林集团品牌的强强结合,是微创集团国际化发展战略的又一重要里程碑,同时也是微创集团自身坚持不懈的内源式发展的重要标志。索林集团是心律管理市场领域中极具创新意识的企业,我们期待为索林集团医疗器械的商业化贡献力量,并为中国患者带来福音。”
 
      “在中国涉足心律管理市场是集团业务长期发展战略中的关键。”索林集团首席执行官André-Michel Ballester同时表示,“微创集团具有良好的品牌价值和知名度,销售网络覆盖面广,且拥有优秀的管理团队,是索林集团在中国心律管理业务上理想的合作伙伴。”
 
      更多详情,可见公司公告:"内幕消息:成立合营企业"

 

关于索林集团
        索林集团(路透社代码:SORN.MI),是一家全球性的医疗器械公司,在心血管疾病治疗中位于国际领先。集团研发、制造并销售用于心脏手术和治疗心脏节律紊乱的医疗器械产品。在全世界各地有3,750名员工。索林集团专注于两大治疗领域:心脏外科手术(开放式心脏手术的心肺产品和心脏瓣膜修复或更换产品)及心脏节律管理(起搏器、除颤器、心脏再同步装置)。
        更多信息,敬请造访公司网站:
www.sorin.com

 

关于微创集团
        微创医疗科学有限公司(HK00853)起源于1998年5月在上海张江高科技园区成立的微创医疗器械(上海)有限公司,为中国领先的高端医疗器械集团,旗下包括上海微创生命科技有限公司、上海微创骨科医疗科技有限公司、上海微创电生理医疗科技有限公司、微创心脉医疗科技(上海)有限公司、微创神通医疗科技(上海)有限公司、微创手术器材(上海)有限公司等多家全资子公司。
        集团始终以创建"一个属于患者和医生的品牌"为己任,业务主要覆盖心血管介入产品、骨科医疗器械、糖尿病及内分泌医疗器械、电生理医疗器械、大动脉及外周血管介入产品、神经介入产品、外科手术等十大领域。
        微创的产品于中国有逾1,200家医院使用,部分产品出口至中国境外的20多个国家,覆盖了亚太地区、南美及欧洲等市场的1,000多家医院。平均每30秒左右,就有一个微创产品在全球的某一个地方用于救治患者的生命或改善其生活品质。微创医疗坚持以人为本在以微创伤为代表的高科技医学领域建设一个属于患者的全球化领先医疗集团。
        更多信息,敬请造访公司网站:
www.microport.com

 

Sorin S.p.A.

MICROPORT SCIENTIFIC CORPORATION AND SORIN GROUP SIGN JOINT VENTURE AGREEMENT FOR CARDIAC RHYTHM MANAGEMENT BUSINESS IN CHINA

 

 

Shanghai, China and Milan, Italy, January 9, 2014 - MicroPort Scientific Corporation (HK: 00853) and Sorin Group (Reuters Code: SORN.MI), announced today that they have entered into a definitive agreement to form a joint venture to market and develop cardiac rhythm management (CRM) devices (implantable pacemakers, defibrillators, cardiac resynchronization devices and related devices) in China. MicroPort will hold a 51 percent stake in the joint venture entity, while Sorin will hold the remaining 49 percent interest. In accordance with the agreement, MicroPort and Sorin shall make initial capital contributions of, respectively, RMB62,220,000 (USD10.2 million) and of RMB59,780,000 (USD9.8 million) in cash in the joint-venture company.
The new venture, which will be named MicroPort Sorin CRM (Shanghai) Co. Ltd., will be located in Shanghai and is scheduled to start operations in the first half of 2014. Under the agreement, the two companies will collaborate, through the joint venture, on the import, sale and service of Sorin's CRM devices in Greater China and, in parallel, in accelerating the development of locally manufactured CRM products for the Chinese market. Significant engineering and development resources from both parties will transition to the joint venture immediately.
This new venture brings together two respected industry leaders, leveraging complementary strengths: MicroPort's unparalleled Chinese market coverage and strong national reputation and Sorin's 40 years' experience in the development and manufacture of high quality and innovative CRM devices. MicroPort and Sorin believe that the joint venture will be well positioned to quickly penetrate the growing CRM market in China. According to industry research, the Chinese CRM market, still underpenetrated, is estimated to be approximately USD500 million, growing approximately 10% per year in the next 5 years.
"This agreement represents a key milestone in MicroPort's strategy, enabling us to enter in the rapidly growing Chinese CRM market and expanding our high-end medical device product portfolio. We recognize Sorin as an innovative player in the CRM field and we are looking forward to supporting the commercialization of Sorin's devices and ultimately realizing our goal to develop locally manufactured devices which are specifically designed for China and fit the needs of the growing demand in our country", commented Dr. Zhaohua Chang, Chairman and Chief Executive Officer of MicroPort Scientific Corporation.
"This is an important milestone in our strategy to build a local presence in China. Access to CRM therapies in China is expected to expand rapidly and the market should grow at double digit rates in the foreseeable future. Expanding our footprint in China in CRM is key to our long-term growth strategy," said André-Michel Ballester, Chief Executive Officer of Sorin Group. "MicroPort, whose strong reputation, broad distribution network and talented management team is recognized by its customers, is the ideal CRM partner for Sorin in China."
The transaction is subject to customary closing conditions, including receipt of regulatory clearances.

 

(来源: 互联网 )


全年征稿 / 资讯合作

联系邮箱:kefu@labbase.net

版权与免责声明

  • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, //www.next-search.com,违反者本网将追究相关法律责任。
  • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
  • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。